Siga Technologies has won a new contract for its oral antiviral drug, Tpoxx, worth up to $10.7 million from the U.S. Department of Defense as the country stocks up on the treatment amid a monkeypox outbreak.
The British scientists behind one of the major therapeutic COVID-19 trials have turned their focus to treatments for monkeypox, a viral disease that has been labeled a global health emergency by the World Health Organization (WHO).
To deal with the rapidly rising monkeypox cases in the country, experts from United States health regulatory agencies have announced plans to conduct a clinical trial to more thoroughly assess the safety and efficacy of TPOXX (tecovirimat) as an antiviral in patients with monkeypox.
Over the weekend, the World Health Organization declared the monkeypox outbreak, so far documented in more than 70 countries, a “public health emergency of international concern [PHEIC].” Here are the initiatives some biopharma companies are taking to contain monkeypox.
The European Union is working on a common purchasing agreement for vaccines and antivirals against monkeypox, as cases of the viral disease usually endemic to Africa gather steam in Europe and beyond.
As cases and news of monkeypox spread globally, scientists are investigating the unprecedented outbreak. BioSpace compiled updates about tracking, origins and treatments concerning monkeypox.